Stage-Specific Alteration and Prognostic Relationship of Serum Fumarate Hydratase Autoantibodies in Gastric Cancer
International Journal of Molecular Sciences · 17.05.2024 · 25 (10) · 5470
DOI: 10.3390/ijms25105470 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.05.2024. Verfasst von Natsuko Sasajima und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Toho University School of Medicine, Tokyo 143-8541, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Fumarate Hydratase, Autoantibodies, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency, JSPS KAKENHI, Toho University School of Medicine.
Abstract (Originalsprache)
The relationship between energy production and cancer is attracting attention. This study aimed to investigate the clinicopathological significance of fumarate hydratase (FH), a tricarboxylic acid cycle enzyme, in gastric cancer using autoantibodies as biomarkers. The study analyzed 116 patients who underwent gastric cancer surgery and 96 healthy controls. Preoperative serum FH autoantibody (s-FH-Ab) titers were analyzed using an immunosorbent assay with an amplified luminescent proximity homogeneous assay. Receiver operating characteristic analysis was used to determine the cutoff s-FH-Ab titer. Clinicopathological factors and prognosis were compared between the high and low s-FH-Ab groups. The s-FH-Ab levels were significantly higher in the gastric cancer group than in the control group (p = 0.01). Levels were elevated even in patients with stage I gastric cancer compared with healthy controls (p = 0.02). A low s-FH-Ab level was significantly associated with distant metastasis (p = 0.01), peritoneal dissemination (p < 0.05), and poor overall survival (p < 0.01). Multivariate analysis revealed that low s-FH-Ab levels were an independent risk factor for poor prognosis (p < 0.01). Therefore, s-FH-Ab levels may be a useful biomarker for early diagnosis and the prediction of prognosis in patients with gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterological Surgery, Toho University School of Medicine, Tokyo 143-8541, Japan.
- Department of Clinical Oncology, Toho University Graduate School of Medicine, Tokyo 143-8541, Japan.
- Port Square Kashiwado Clinic, Kashiwado Memorial Foundation, Chiba 260-0025, Japan.
- Department of Neurological Surgery, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.
ORCID-Profile: Yoko Oshima, Hao Wang, Bo-Shi Zhang
Förderung
- Japan Science and Technology Agency
- JSPS KAKENHI
- Toho University School of Medicine
Zitieren
APA
Sasajima, N., Sumazaki, M., Oshima, Y., Ito, M., Yajima, S., Takizawa, H., Wang, H., Li, S. Y., Zhang, B. S., Yoshida, Y., Hiwasa, T., & Shimada, H. (2024). Stage-Specific Alteration and Prognostic Relationship of Serum Fumarate Hydratase Autoantibodies in Gastric Cancer. International Journal of Molecular Sciences, 25(10), 5470. https://doi.org/10.3390/ijms25105470
Vancouver
Sasajima N, Sumazaki M, Oshima Y, Ito M, Yajima S, Takizawa H, et al. Stage-Specific Alteration and Prognostic Relationship of Serum Fumarate Hydratase Autoantibodies in Gastric Cancer. International Journal of Molecular Sciences. 2024;25(10):5470. doi:10.3390/ijms25105470
BibTeX
@article{Sasajima2024,
author = {Sasajima, Natsuko and Sumazaki, Makoto and Oshima, Yoko and Ito, Masaaki and Yajima, Satoshi and Takizawa, Hirotaka and Wang, Hao and Li, Shu-Yang and Zhang, Bo-Shi and Yoshida, Yoichi and Hiwasa, Takaki and Shimada, Hideaki},
title = {Stage-Specific Alteration and Prognostic Relationship of Serum Fumarate Hydratase Autoantibodies in Gastric Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {10},
pages = {5470},
doi = {10.3390/ijms25105470}
}
EUVIMED